Similar Items: Neuroprotection trial design in progressive supranuclear palsy: challenges and solutions
- CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
- The utility of a composite endpoint for tracking disease progression in Lewy body dementia
- Automated analysis of expressive prosody in Dutch patients with behavioral variant frontotemporal dementia and primary progressive aphasia
- Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials
- From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series
- A Scoping Review on the Attributes of Cluster Randomized Controlled Trials in Long-Term Care Facilities